クローン病の管理と治療に役立つ CDPATH™ の研究 (COMPASS-CD)
クローン病リスク予測ツールである CDPATH™ の実世界での使用を評価する第 4 相試験
CDPATH™ is a tool to help predict the potential for developing Crohn's disease related complications in certain adult participants within 3 years. The main aim of the study is to explore the use of CDPATH™ to describe a participant's risk profile and to have discussions with their doctor about the potential path of their Crohn's disease. The number of visits will be decided by the study clinic according to their standard practice.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
詳細な説明
The tool being tested in this study is called CDPATH™. CDPATH™ is being used to provide a graphical representation of an individual participant's risk of developing a CD-related complication within three years, leveraging known participant risk factors based on clinical, serologic and genetic variables to help people categorize risk who have CD. This study will gather data on the use of the tool in real-world settings to inform practical use of CDPATH™.
The study will enroll approximately 200 patients. Participants and health care providers (HCPs) will be surveyed to understand their satisfaction with the CDPATH™ process and with their treatment choice.
This multi-center trial will be conducted in the United States. The overall time to participate in this study is 36 months. Participants will make multiple visits to the HCP's clinic, and data will be collected approximately every six months up to 3 years, based on the timing of routine follow-up appointments for assessment.
研究の種類
研究の種類
入学 (実際)
入学
段階
段階
- フェーズ 4
連絡先と場所
研究場所
-
-
Arizona
-
Phoenix、Arizona、アメリカ、85032
- Arizona Arthritis & Rheumatology Research, PLLC
-
-
California
-
Loma Linda、California、アメリカ、92357
- VA Loma Linda Healthcare System
-
Murrieta、California、アメリカ、92563
- United Medical Doctors
-
Newport Beach、California、アメリカ、92663
- University of Southern California Medical Center
-
Orange、California、アメリカ、92868
- University of California at Irvine Medical Center
-
Orange、California、アメリカ、92868
- Clinnova Research Solutions
-
-
Colorado
-
Aurora、Colorado、アメリカ、80014
- Kaiser Permanate of Colorado
-
-
Connecticut
-
Hamden、Connecticut、アメリカ、06518
- Medical Research Center of Connecticut, LLC
-
-
Florida
-
Clearwater、Florida、アメリカ、33762
- West Central Gastroenterology d/b/a Gastro Florida
-
Pensacola、Florida、アメリカ、32503
- Gastroenterology Associates of Pensacola, PA
-
-
Idaho
-
Idaho Falls、Idaho、アメリカ、83404
- Grand Teton Research Group, PLL
-
-
Illinois
-
Arlington Heights、Illinois、アメリカ、60005
- GI Alliance
-
Gurnee、Illinois、アメリカ、60031
- GI Alliance
-
Northbrook、Illinois、アメリカ、60062
- Comprehensive Gastrointestinal Health
-
Rockford、Illinois、アメリカ、61107
- Rockford Gastroenterology Associates, Ltd.
-
-
Indiana
-
Indianapolis、Indiana、アメリカ、46202
- Indiana University
-
-
Iowa
-
Clive、Iowa、アメリカ、50325
- Iowa Digestive Disease Center
-
Iowa City、Iowa、アメリカ、52242-1009
- University of Iowa Hospitals & Clinics
-
-
Kansas
-
Kansas City、Kansas、アメリカ、66160
- University of Kansas Medical Center Research Institute, Inc.
-
-
Louisiana
-
Baton Rouge、Louisiana、アメリカ、70809
- GI Alliance - Baton Rouge
-
Shreveport、Louisiana、アメリカ、71105
- Louisiana Research Center, LLC
-
-
Maryland
-
Columbia、Maryland、アメリカ、21045
- Gastro Center of Maryland
-
-
Massachusetts
-
Burlington、Massachusetts、アメリカ、01805
- Lahey Clinic Inc. - PARENT ACCOUNT
-
Worcester、Massachusetts、アメリカ、01655
- UMASS Memorial Medical Center
-
-
New Mexico
-
Albuquerque、New Mexico、アメリカ、87131-0001
- University of New Mexico
-
-
New York
-
New York、New York、アメリカ、10075-1850
- Lenox Hill Hospital
-
-
Ohio
-
Beavercreek、Ohio、アメリカ、45431
- Clinical Inquest Center Ltd
-
Dayton、Ohio、アメリカ、45415
- Dayton Gastroenterology, Inc
-
-
Oregon
-
Portland、Oregon、アメリカ、97220-9442
- The Oregon Clinic, P.C.
-
-
Pennsylvania
-
Camp Hill、Pennsylvania、アメリカ、17011
- Susquehanna Research Group, LLC
-
Pittsburgh、Pennsylvania、アメリカ、15213
- University of Pittsburgh Medical Center Health System
-
Pittsburgh、Pennsylvania、アメリカ、15212
- Allegheny Center for Digestive Health
-
Uniontown、Pennsylvania、アメリカ、15401
- Frontier Clinical Research, LLC
-
-
South Carolina
-
Summerville、South Carolina、アメリカ、29486
- Palmetto Primary Care Physician Division of Gastroenterology
-
-
South Dakota
-
Rapid City、South Dakota、アメリカ、57701
- Rapid City Medical Center, LLC
-
-
Tennessee
-
Nashville、Tennessee、アメリカ、37204
- Vanderbilt University Medical Center
-
-
Texas
-
Austin、Texas、アメリカ、78712
- The University of Texas at Austin
-
Houston、Texas、アメリカ、77030
- Baylor College of Medicine
-
Southlake、Texas、アメリカ、76092
- GI Alliance - Southlake
-
-
Utah
-
Ogden、Utah、アメリカ、84403
- Care Access Research Berkley
-
Salt Lake City、Utah、アメリカ、84132
- University of Utah
-
-
Virginia
-
Fairfax、Virginia、アメリカ、22031
- GCGA Physicians LLC
-
Lynchburg、Virginia、アメリカ、24502
- Gastroenterology Associates
-
-
Washington
-
Bellevue、Washington、アメリカ、98405
- GI Alliance
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Has an initial diagnosis of CD established within five years prior to screening by clinical and endoscopic evidence and corroborated by a histopathology report (if available).
- Has agreed to use the CDPATH™ tool.
- Has reliable access to the internet and is willing to answer electronic patient-reported outcomes (ePROs) throughout the study.
Exclusion Criteria:
- Has had known complications from CD including but not limited to: bowel stricture, CD-related intra-abdominal abscess, internal penetrating disease (known fistula other than perianal fistula), non-perianal surgery, bowel resection, or stricturoplasty. A perianal fistula or abscess without other signs of penetrating disease is allowed.
- Has had any non-CD-related abdominal surgery.
- Has received investigational biologic or nonbiologic agents for the treatment of CD in an investigational protocol. Approved biologic or nonbiologic agents for CD are allowed.
- Has previously used CDPATH™ or PROSPECT results to assess CD risk for complications.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:診断
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的:CDPATH™
Participants with CD will be using CDPATH™ tool. Clinical data will be collected via an ongoing registry. Participants and health care provider (HCP)-reported outcomes data will be collected periodically once every 6 months for up to 36 months via electronic surveys. Two baseline blood samples will be collected at screening for CDPATH™ analysis. 1 additional sample will be collected for future potential biomarker analysis. |
Crohn's disease risk prediction tool.
他の名前:
Three blood samples will be drawn. |
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Percentage of Participants in Real-world Practice in Each Risk Category at Baseline Based on the CDPATH™ Tool Results
時間枠:Baseline (Day 1)
|
The risk profile of an individual participant with CD is the output of the CDPATH™ tool. Categories for CD includes low, medium, high risk of developing a CD complication within 3 years. |
Baseline (Day 1)
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Percentage of Participants with Specific Treatment Path and Choice Based on CDPATH™ Tool, Stratified According to Risk Category
時間枠:Up to 36 months
|
Treatment path (i.e., sequence over time) and choice, by low, medium and high risk, will be chosen to characterize treatment path and choice based on risk stratification. |
Up to 36 months
|
|
Change From Baseline in Decisional Conflict Scale (DCS) Score
時間枠:Baseline, then every 6 months up to 36 months
|
DCS is a validated electronic patient-reported outcome (ePRO) collected via electronically administered patient surveys. It measures personal perceptions of the following responses: uncertainty in choosing options, modifiable factors contributing to uncertainty such as feeling uninformed, unclear about personal values and unsupported in decision making, and effective decision making such as feeling the choice is informed, values-based, likely to be implemented and expressing satisfaction with the choice. DCS involves answering 11 questions of PRO, of which 10 questions can be answered as yes (score = 0) or unsure (score = 2) or no (score =4). The total score will range from 0 to 40. Higher score indicates higher decisional conflict. |
Baseline, then every 6 months up to 36 months
|
|
Change From Baseline in Work Productivity and Activity Impairment Questionnaire - CD Version (WPAI-CD) Score
時間枠:Baseline, then every 6 months up to 36 months
|
WPAI-CD is a validated ePRO collected via electronically administered patient surveys. It consists of six questions that evaluate 4 domain scores: absenteeism (i.e., work time missed), presenteeism (i.e., reduced work productivity), overall work impairment, and activity impairment. Scores are expressed as a percentage of impairment, where higher scores indicate greater impairment and reduced productivity. The total score ranges from 0 (no impairment) to 100% (total loss of work productivity). |
Baseline, then every 6 months up to 36 months
|
|
Change From Baseline in Patient-Reported Outcomes Measurement Information System (PROMIS) Global Health Scale Score
時間枠:Baseline, then every 6 months up to 36 months
|
PROMIS Global Health scale is a validated ePRO collected via electronically administered patient surveys. It is a 10-item PRO measuring the overall evaluation of one's physical and mental health. The total score ranges from 0 to 100. The final score will be represented by the T-score metric, in which 50 is the mean of a relevant reference population and 10 is the standard deviation (SD) of that population. A higher PROMIS T-score represents more of the concept being measured (higher Global Health score indicate better health). |
Baseline, then every 6 months up to 36 months
|
|
Patient-Reported Satisfaction and Experience Score with the CDPATH™ Tool
時間枠:Up to 36 months
|
Participant's satisfaction and experience with the CDPATH™ tool will be assessed based on 15 questions. Negative responses/lower score to/in these questions indicates less satisfaction whereas positive responses/higher score indicates satisfaction with the tool. |
Up to 36 months
|
|
Number of Participants with Clinical Outcomes
時間枠:Up to 36 months
|
Participants with clinical outcomes describing the disease burden based on treatment path and controlling for risk strata will be reported. |
Up to 36 months
|
|
Percentage of Participants with Healthcare Resource Utilization
時間枠:Up to 36 months
|
Healthcare resource includes healthcare provider (HCP) visits/referrals, visit to emergency room, hospitalizations, surgery, new CD-related complications, and diagnostic evaluations (e.g., imaging, colonoscopy, etc.). |
Up to 36 months
|
|
Change from First Assessment in Health Care Provider (HCP)-reported Assessment of the Feasibility and Usability of the CDPATH™ Tool
時間枠:First assessment (6 months after HCPs first enrolled participant) up to HCP leaves the study or the study ends (up to 36 months)
|
HCP-reported CDPATH™ satisfaction data will be collected directly from HCPs via electronically administered HCP surveys and entered into the eCRF. HCPs will be queried regarding their satisfaction and experience with the general process, the ease of incorporating the tool in their everyday practice, and the impact of the tool on their treatment recommendations and participant communications. For the 6 questions, HCP will rate on 1-5 scale where, 1=strongly disagree and 5=strongly agree. For remaining 4 questions, written feedback from HCP will be consider. Overall positive responses will indicate higher feasibility and usability. |
First assessment (6 months after HCPs first enrolled participant) up to HCP leaves the study or the study ends (up to 36 months)
|
協力者と研究者
捜査官
捜査官
- スタディディレクター:Study Director、Takeda
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (実際)
一次修了
研究の完了 (実際)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
その他の研究ID番号
- Vedolizumab-4015
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
IPD 共有アクセス基準
IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
IPD 共有サポート情報タイプ
- STUDY_PROTOCOL
- SAP
- ICF
- CSR
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。